Table 2.
Comparison of immune cell subset infiltration in relation to CXCL10 expression in DCIS and invasive carcinoma.
| Immune cell subset | DCIS | p value | Invasive carcinoma | p value | ||
|---|---|---|---|---|---|---|
| CXCL10 (+) | CXCL10 (−) | CXCL10 (+) | CXCL10 (−) | |||
| Total | ||||||
| CD4+ TIL | 77.33 (23.50–116.67) | 25.1 (7.00–52.75) | 0.001 | 72.50 (35.25–155.50) | 88.00 (47.00–186.00) | 0.507 |
| CD8+ TIL | 36.33 (16.33–66.83) | 12.33 (5.50–25.67) | 0.001 | 120.00 (56.75–249.00) | 65.00 (32.50–142.00) | 0.008 |
| FOXP3+TIL | 4.67 (0.00–12.83) | 0.00 (0.00–2.00) | < 0.001 | 13.00 (5.00–21.00) | 5.00 (2.00–12.50) | 0.001 |
| PD-L1+ IC | 11/21 (52.4) | 34/200 (17.0) | < 0.001 | 24/36 (66.7) | 40/113 (35.4) | 0.001 |
| HR + subgroup | ||||||
| CD4+ TIL | 58.83 (21.42 -104.58) | 18.00 (5.00–47.08) | 0.004 | 91.00 (38.75–160.25) | 88.00 (49.00–172.00) | 0.890 |
| CD8+ TIL | 31.67 (13.91–52.08) | 11.33 (5.00–22.00) | 0.006 | 70.00 (56.00–206.00) | 58.00 (30.00–130.00) | 0.120 |
| FOXP3+TIL | 0.50 (0.00–5.33) | 0.00 (0.00–0.00) | 0.024 | 7.00 (3.50–18.50) | 5.00 (2.00–11.00) | 0.179 |
| PD-L1+ IC | 6/14 (42.9) | 20/156 (12.8) | 0.009 | 7/18 (38.9) | 29/62 (31.9) | 0.563 |
| HR- subgroup | ||||||
| CD4+ TIL | 109.33 (23.33–126.00) | 50.17 (24.58–96.33) | 0.175 | 70.00 (33.75–157.00) | 106.00 (32.25–228.75) | 0.563 |
| CD8+ TIL | 49.0 (31.00–76.33) | 20.17 (8.25–51.75) | 0.124 | 133.50 (89.00–322.50) | 109.00 (36.00–262.00) | 0.262 |
| FOXP3+TIL | 15.00 (8.00–17.33) | 2.50 (0.00–7.75) | 0.001 | 16.50 (10.75–31.50) | 8.00 (3.75–15.00) | 0.019 |
| PD-L1+ IC | 5/7 (71.4) | 14/44 (31.8) | 0.087 | 17/18 (94.4) | 11/22 (50.0) | 0.002 |
P values are calculated by Mann–Whitney U test.
Data are shown in are presented as median (interquartile range) for CD4+, CD8+, and FOXP3+ tumor infiltrating lymphocyte (TIL) subsets and frequency (%) for PD-L1+ immune cell (IC).